Clinical Trial Update: Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial) [Phase 2]

View source ↗

Summary

A phase 2 AIM trial evaluating immune modulation with abemaciclib in head and neck squamous cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: University of Arizona | Conditions: HNSCC | Phase 2 | Status: TERMINATED